Cell transfer regimens in patients with highly advanced surgically unresectable non-small cell lung cancer: Significantly improved overall survival in patients with lower levels of serum immunosuppressive acidic protein

Lung Cancer

Volumn 60, Issue 2, 2008, Pages 246-251

  Ebina, Takusaburo ^a   Fujimiya, Yoshiaki ^b  

^a Center for Immunotherapy against Cancer   (Japan)

^b Hachinohe University   (Japan)

Author keywords

Cell transfer; Immunosuppressive acidic protein, Overall survival; Non small cell lung cancer

Indexed keywords

ALPHA2A INTERFERON; IMMUNOSUPPRESSIVE ACID PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CELL COUNT; CELL TRANSFER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; THERAPY EFFECT;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; KAPLAN-MEIERS ESTIMATE; KILLER CELLS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 42949095228     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.09.016     Document Type: Article

References (38)

1. Keller S.M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 343 (2002) 1217-1222
2. Scagliotti G.V., Fossati R., Torri V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95 (2003) 1453-1461
3. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-61.
4. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
5. Issell B.F., Valdivieso M., Hersh E.M., et al. Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treat Rep 62 (1978) 1059-1063
6. Chahinian A.P., Goldberg J., Holland J., et al. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer. Cancer Treat Rep 66 (1982) 1291-1297
7. Robinson E., Haim N., Segal R., et al. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy). Cancer Treat Rep 69 (1985) 251-258
8. Yamaguchi T., Fujimiya Y., Katakura R., et al. A simple method for the propagation and purification of γδT cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. J Immunol Methods 205 (1997) 19-28
9. - γδT cells from glioblastoma patients. Clin Cancer Res 3 (1997) 633-643
10. Ebina T., Ogama N., Shimanuki H., et al. Effector mechanisms and clinical response of BAK (BRM-activated killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (neuro-immune-endocrine) cells. Microbiol Immunol 45 (2001) 403-411
11. Ebina T., Ogama N., Shimanuki H., et al. Life prolonging effect of immunocell BAK (BRM-Activated Killer) therapy from advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. Cancer Immunol Immunother 52 (2003) 555-560
12. Baccus H. Serum glycoproteins in cancer. Prog Clin Pathol 6 (1975) 111-135
13. Chiu K.M., Mortensen R.F., Osmand A.P., and Gewurz H. Interaction of α1-acid glycoprotein with the immune system. Immunology 32 (1977) 997-1005
14. Tamura K., Shibata Y., Matsuda Y., and Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascetic fluids of cancer patients. Cancer Res 41 (1981) 3244-3252
15. Sakamoto J., Koike A., Saji S., et al. Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK. Surg Today 22 (1992) 530-536
16. Sakamoto J., Teramukai S., Koike A., et al. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Cancer 77 (1996) 2206-2212
17. Araki K., Igarashi T., Tobe T., et al. Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy. Urology 68 (2007) 1178-1182
18. Mountain C.F. A new international staging system for lung cancer. Chest 89 (1986) 225S-2233S
19. Ebina T., Fujimiya Y., Yamaguchi T., et al. The use of BRM-activated killer cells in adoptive immunotherapy: A pilot study with nine advanced cancer patients. Biotherapy 1 (1998) 241-253
20. Shibata M., Takekawa M., and Amano S. Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer. Surg Today 28 (1998) 884-888
21. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 15 (1982) 649-655
22. Pross H.F., Baines M.G., Rubin P., et al. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cell IX. The quantitation of natural killer cell activity. J Clin Immunol 1 (1981) 51-63
23. Dosiou C. Gudice natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocr Rev 26 (2004) 44-62
24. Ziegler S.F., Ramsdell F., and Alderson M.R. The activation antigen CD69. Stem Cells 12 (1994) 456-465
25. Breathnach O.S., Freidlin B., Conley B., et al. Twenty-two years of phase III trilas for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol 19 (2001) 1734-1742
26. Non-Small Cell Lung Cancer Cooperative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
27. Flehinger B.S., Kimmel M., and Melamed M.R. The effect of surgical treatment on survival from early lung cancer; implication for screening. Chest 101 (1992) 1013-1018
28. Hoffman P.C., Mauer A.M., and Vokes E.E. Lung cancer. Lancet 355 (2000) 479-485
29. Suzuki Y., Fujimiya Y., Ohno T., et al. Enhancing effect of tumor necrosis factor (TNF)-α, but not IFN-γ, on the tumor-specific cytotoxicity of γδT cells from glioblastoma patients. Cancer Lett 140 (1999) 161-167
30. Sicard H., Ingoure S., Luciani B., et al. In vivo immunomanipulation of Vγ9δ2T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 175 (2005) 5471-5480
31. Sun S., Zhang X., Tough D.F., and Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 188 (1998) 2335-2342
32. Kranzer K., Bauer M., Lipford G.B., et al. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-γ production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology 99 (2000) 170-178
33. Moretta A., Poggi A., Pende D., et al. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor αβ. J Exp Med 174 (1991) 1393-1398
34. Hansson M., Romeo A., Thoren F., et al. Activation of cytotoxic lymphocytes by interferon-α: role of oxygen radical-producing mononuclear phagocytes. J Leukoc Biol 76 (2004) 1207-1213
35. Wenzel J., Bekisch B., Uerlich M., et al. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Pathol 124 (2005) 37-48
36. Ferrarini M., Heltai S., Pupa S.M., et al. Killing of lamin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing γδT-cell receptors. J Natl Cancer Inst 88 (1996) 436-441
37. Mitropoulos D., Kooi S., Rodriguez-Villanueva J., and Platsoucas C.D. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin Exp Immunol 97 (1994) 321-327
38. Zheng B.J., Chan K.W., Im S., et al. Anti-tumor effects of human T cells in a mouse tumor model. Int J Cancer 92 (2001) 421-425